Preclinical and early-phase clinical data suggest that immune modulation represents a
treatment strategy that is worthy of further investigation in relapsed epithelial ovarian
cancer. One method by which tumor cells may evade immune surveillance is by activation of the
programmed cell death (PD-1) pathway, mediated by expression of PD-1 on the surface of T
lymphocytes, which conveys an inhibitory signal after binding to its ligand PD-L1 on the
surface of tumor cells. Nivolumab and Ipilimumab have shown activity as monotherapies in
solid tumors and very early data suggest that nivolumab may be particularly active for
ovarian clear cell carcinoma.(Hamanishi et al., 2015). Given the uniformly poor prognosis for
patients with clear cell carcinoma in general, we are interested in formally evaluating this
agent in all extra-renal clear cell carcinomas.
Fallopian Tube Cancer,
Clear cell adenocarcinoma,
Primary Peritoneal Cancer,
Primary Peritoneal Carcinoma,
Recurrent Ovarian Cancer,
Extra Renal Origin,
cancer of the ovary,
clear cell carcinoma,
fallopian tube cancers,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.